Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HKEX, SFC Launch TECH; Specialist Technology/ Biotech Firms Allowed to Submit Listing Applications Confidentially
Recommend 13 Positive 24 Negative 6 |
||||
|
||||
|
The Securities and Futures Commission (SFC) and HKEX (00388.HK), a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited, jointly announced today (6th) the launch of a dedicated Technology Enterprises Channel (TECH) to further facilitate New Listing applications from prospective Specialist Technology Companies and Biotech Companies, as well as a new confidential filing option for these companies. In addition, the Exchange has updated the Guide for New Listing Applicants (the Guide) that these companies are presumed to have satisfied the Innovative Company Requirements and the external validation requirement for listing with a weighted voting right (WVR) structure under Main Board Chapter 8A. TECH supports prospective Specialist Technology Companies and Biotech Companies in understanding applicable Listing Rules and preparing for their listing in Hong Kong before submitting formal New Listing applications through the following measures offered by the Exchange: (1) Dedicating a specialized team with relevant experience in reviewing and providing guidance on Main Board Chapters 18C and 18A applications; (2) Engaging with prospective companies to gain deeper knowledge of their specific businesses and facilitate their comprehension of Listing Rule requirements; (3) Providing guidance on the eligibility and suitability for listing, such as the requirements for Core Products, the acceptance of other biotech products and/or clinical trials done under the regulation of different authorities, the qualifications and independence of Sophisticated Investors, acceptable sectors for Specialist Technology Industries, as well as factors for accepting new sectors/ industries outside the current scope; and (4) Providing opportunities to discuss and seek the Exchange’s preliminary guidance on case-specific issues arising under the Listing Rules. Since Specialist Technology Companies and Biotech Companies are typically companies that are in their early stage of development or have yet to commercially launch their products, premature and prolonged disclosure of information on these companies’ operational strategies, proprietary technologies, and listing plans may pose heightened and disproportionate risks compared to other industries. To assist these companies in mitigating these risks, the Exchange will permit these companies seeking a listing under Main Board Chapters 18C and 18A to submit their Application Proofs5 confidentially. For further details, please refer to Chapter 6.4 of the Guide. The confidential filing option shall be available for listing applications filed under Main Board Chapters 18C and 18A after today. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
